FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to virology, immunology, molecular biology and gene engineering. What is presented is a respiratory syncytial virus (RSV) fused (F) protein for eliciting an immune response, wherein the above RSV F protein contains a deletion of one or more amino acids of a fusion domain, wherein the above fusion domain corresponds to amino acids 137-154 of RSV F wild-type protein (SEQ ID NO:2); and an inactivated primary site of furin splitting, wherein the primary site of furin splitting corresponds to amino acid 131-136 of RSV F wild-type protein (SEQ ID NO: 2), wherein the inactivation is performed by mutation; as well as nucleic acid coding the given protein, a cell, a vaccine composition, a micelle and a virus-like particle.
EFFECT: invention can be used for treating and preventing RSV infection.
25 cl, 22 dwg, 11 ex
Authors
Dates
2014-10-20—Published
2009-12-09—Filed